Clinical Validation of Targeted Solid Tumor Profiling.

Area of Science:

• Oncology
• Genomics
• Molecular Diagnostics

Background:

• Large-scale tumor profiling generates vast data, identifying driver and passenger mutations.
• Somatic mutations are vital for accurate tumor diagnosis, prognosis, and targeted therapies.
• Personalized medicine relies on broad somatic mutation identification via next-generation sequencing (NGS).

Purpose of the Study:

• To describe performance characteristics and quality metrics for diagnostic validation of tumor profiling.
• To ensure NGS implementation in molecular diagnostics meets international medical laboratory standards (e.g., ISO15189:2012).
• To minimize false positives and negatives for highly accurate and robust clinical data.

Main Methods:

• Analysis of performance characteristics and quality metrics for the entire NGS workflow.
• Implementation of assays to assess precision, limit of detection, accuracy, sensitivity, specificity, and robustness.
• Validation aligned with international standards for medical laboratories.

Main Results:

• Detailed description of essential metrics for robust diagnostic validation of tumor profiling.
• Established quality metrics cover the complete workflow from DNA enrichment to final reporting.
• Validation approach ensures adherence to stringent international standards.

Conclusions:

• Robust validation of NGS-based tumor profiling is essential for reliable molecular diagnostics.
• Defined performance characteristics and quality metrics ensure accuracy and robustness in clinical data.
• Adherence to standards like ISO15189:2012 is critical for clinical implementation of NGS in oncology.